Ketamine Use Among People Who Regularly Use Ecstasy and Other Illicit Stimulants in Australia: Trends and Characteristics of Use, 2009-2019.
Adult
Australia
Central Nervous System Stimulants
/ administration & dosage
Cross-Sectional Studies
Female
Harm Reduction
Humans
Illicit Drugs
Ketamine
/ administration & dosage
Male
N-Methyl-3,4-methylenedioxyamphetamine
/ administration & dosage
Substance-Related Disorders
/ epidemiology
Young Adult
Journal
Journal of studies on alcohol and drugs
ISSN: 1938-4114
Titre abrégé: J Stud Alcohol Drugs
Pays: United States
ID NLM: 101295847
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
entrez:
7
4
2021
pubmed:
8
4
2021
medline:
16
6
2021
Statut:
ppublish
Résumé
Ketamine is a dissociative anesthetic used in medical practice, used recreationally since the mid-1960s. This study describes trends in ketamine use in sentinel cross-sectional samples of Australians who regularly use illicit stimulants, along with characteristics of consumers. Data on trends in recent ketamine use (i.e., use in past 6 months) were drawn from annual interviews (approximately 800/year) with cross-sectional samples of people recruited from Australian state capitals from 2009 to 2019 as part of the Ecstasy and Related Drugs Reporting System (EDRS) study. Characteristics of those reporting recent use were examined in the 2019 EDRS data set (n = 728) using logistic regression. Recent ketamine use increased between 2009 and 2019 (10% to 41%, respectively, p < .001), primarily driven by use among participants recruited in Melbourne (21% to 84%, p < .001) and Sydney (19% to 68%, p < .001). However, frequency of use remained low. In 2019, consumer characteristics associated with use included being born outside of Australia and residing in Sydney or Melbourne (compared with Canberra). Among EDRS participants in Australia, we observed an increase in recent ketamine use between 2009 and 2019, although indicators of potential problematic use remained low. The increase in recent ketamine use was largely driven by increases in Melbourne and Sydney. Further research on drivers of use in these cities is required to effectively inform harm-reduction strategies.
Substances chimiques
Central Nervous System Stimulants
0
Illicit Drugs
0
Ketamine
690G0D6V8H
N-Methyl-3,4-methylenedioxyamphetamine
KE1SEN21RM
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
188-196Déclaration de conflit d'intérêts
Paul Dietze has received investigator-driven funding from Gilead Sciences and Indivior for work unrelated to this study. Paul Dietze and Simon Lenton have served as unpaid members of an Advisory Board for an intranasal naloxone product. Amy Peacock has received investigator-driven united educational funding from Mundipharma and Seqirus for work unrelated to this study. All other authors have no competing interests to declare.